Ellen K. Donnelly
Chief Executive Officer
Haematology
Modus Therapeutics AB
Sweden
Biography
Dr. Ellen K. Donnelly, Ph.D has been the Chief Executive Officer of Modus Therapeutics AB since April 25, 2017. Dr. Donnelly served for Pfizer, Inc., where she held various leadership positions in Clinical Operations; Project and Portfolio Management; and Research. Where, Dr. Donnelly was responsible for Clinical Operations for Pfizer’s Neuroscience and Pain therapeutic area. Dr. Donnelly has biotech and consulting experience to the Chief Executive Officer role, having worked in positions within U.S. biotech and management consulting prior to her time at Pfizer. Dr. Donnelly received her Ph.D. from Yale University
Research Interest
Haematology
